Our current clinical projects

Projects for licensing

Project & Mechanism
Disease areas
Preclinical
Phase I
Phase II
Phase III
Market

MIV-818

Nucleotide DNA polymerase inhibitor (oral)

Hepatocellular carcinoma

Proprietary projects

Project & Mechanism
Disease areas
Preclinical
Phase I
Phase II
Phase III
Market

Remetinostat

HDAC inhibitor (topical)

Cutaneous T-cell lymphoma (MF)1)

Basal cell carcinoma

test

Birinapant

SMAC mimetic (intravenous)

Solid tumors (Keytruda® combination)

MIV-711

Cathepsin K inhibitor (oral)

Osteoarthritis

1) Test footnote

Partnerships projects

Project & Mechanism
Disease areas
Preclinical
Phase I
Phase II
Phase III
Market

MIV-802

Nucleotide NS5B polymerase inhibitor

Hepatitis C - Phase I

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

Labial herpes

Our current clinical projects

Proprietary

Remetinostat

HDAC inhibitor (topical)

  • Mechanism

    HDAC inhibitor (topical)

  • Disease area

    Cutaneous T-cell lymphoma (MF)1)

    Phase II

    Basal cell carcinoma

    Phase I

    test

    Market

Birinapant

SMAC mimetic (intravenous)

  • Mechanism

    SMAC mimetic (Intravenous)

  • Disease area

    Solid tumors (Keytruda® combination)

    Phase I

MIV-711

Cathepsin K inhibitor (oral)

  • Mechanism

    Cathepsin K inhibitor

  • Disease area

    Osteoarthritis

    Phase II

1) Test footnote

Partnerships

MIV-802

Nucleotide NS5B polymerase inhibitor

  • Mechanism

    Nucleotide NS5B polymerase inhibitor

  • Disease area

    Hepatitis C - Phase I

    Preclinical

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

  • Mechanism

    Hydrocortisone and aciclovir combination

  • Disease area

    Labial herpes

    Market